Mitoxantrone and etoposide: An effective regimen for refractory or relapsed acute myelogenous leukemia
暂无分享,去创建一个
M. Lazzarino | P. Bernasconi | S. Merante | E. Orlandi | C. Bernasconi | G. Pagnucco | M. Bonfichi | D. Inverardi | E. Alessandrino | E. Morra | E. Morra | E. P. Alessandrino | M. Lazzarino | G. Pagnucco | S. Merante | M. Bonfichi
[1] M. Björkholm,et al. Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia. , 1990, Oncology.
[2] F. Mandelli,et al. Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia. , 1989, Leukemia.
[3] E. Estey,et al. Mitoxantrone and high‐dose cytosine arabinoside in refractory acute myelogenous leukemia , 1988, Cancer.
[4] J. Bennett,et al. Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. , 1988, Blood.
[5] T. Lipp,et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Grever. Treatment of patients with acute nonlymphocytic leukemia not in remission. , 1987, Seminars in oncology.
[7] J. Dutcher,et al. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. , 1987, Leukemia.
[8] R. Marcus,et al. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia. , 1987, Cancer treatment reports.
[9] T. Lipp,et al. Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia. , 1986, Cancer treatment reports.
[10] H. Lazarus,et al. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Wittes,et al. Etoposide (VP-16-213). Current status of an active anticancer drug. , 1985, The New England journal of medicine.
[12] P. Schein,et al. Clinical pharmacology of daunorubicin in phase I patients with solid tumors: development of an analytical methodology for daunorubicin and its metabolites. , 1984, Seminars in oncology.
[13] J. Holland,et al. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. , 1984, Seminars in oncology.
[14] M. Oken,et al. A phase II trial of VP 16–213 in adults with refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group study , 1984, American journal of clinical oncology.
[15] J. Misset,et al. Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas , 1974, Cancer.